IDH1 and central nervous system cancer: Although the mutation of isocitrate dehydrogenase enzyme (IDH) has been proven to be an inciting event in glioma‐genesis, recent genome‐wide mutation analyses have revealed the prevalence of IDH mutations in more than 70% of WHO grade II and III gliomas or secondary GBMs, whereas fewer than 5% of primary GBMs harbor this mutation.43